TM-S Trabecular Metal™ Cervical Interbody Fusion Device Receives FDA Clearance

PR Newswire

SAN DIEGO, Feb. 18, 2011

SAN DIEGO, Feb. 18, 2011 /PRNewswire/ — Zimmer Holdings, Inc. (NYSE: ZMH; SIX: ZMH), a leader in musculoskeletal care, today announced it has received FDA clearance for the TM-S Trabecular Metal™ Cervical Interbody Fusion Device.  The TM-S system is the industry’s first cervical interbody device incorporating porous metal technology, and the first Zimmer Trabecular Metal device for cervical interbody fusion (IBF) in the United States.

The TM-S system is constructed from Zimmer’s proprietary Trabecular Metal Technology, a unique porous metal biomaterial with structural and mechanical properties similar to cancellous bone.  Trabecular Metal Material provides an osteoconductive scaffold which supports bony in-growth and vascularization into the implant.  Utilized in cervical interbody fusion, the properties of Trabecular Metal Material provide an excellent environment for bone growth.  

“With the introduction of the TM-S system, Zimmer is bringing the potential benefits of porous metal technology to cervical interbody fusion,” said Steve Healy, President, Zimmer Spine.  ”The osteoconductive properties of Trabecular Metal Technology support initial fixation and can potentially aid in cervical fusion.”

The TM-S Cervical Fusion Device is intended for use with supplemental fixation systems and with autogenous bone graft.  The device is designed to treat the cervical spine of patients with degenerative disc disease with or without radicular symptoms at one level from C2-T1.  

The TM-S Cervical Fusion Device will be on display at the 2011 American Academy of Orthopaedic Surgeons (AAOS) annual meeting.  Zimmer Spine will also be hosting hands-on training for the device at the Company’s exhibit at AAOS 2011.  For more information about Trabecular Metal Technology, visit zimmer.com.

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products.  Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries.  Zimmer’s 2010 sales were approximately $4.2 billion. the Company is supported by the efforts of more than 8,000 employees worldwide.

ZimmerSafeHarbor Statement

This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management’s beliefs and assumptions made by management.  Forward-looking statements may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “assumes,” “guides,” “targets,” “forecasts,” and “seeks” or the negative of such terms or other variations on such terms or comparable terminology.  These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially.  For a list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission.  We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports.  Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. this cautionary statement is applicable to all forward-looking statements contained in this document.

SOURCE Zimmer Holdings, Inc.

PR Newswireprnewswire.co.uk/

Last updated on: 18/02/2011 13:00:07

Press Release Source: Crohn’s & Colitis Foundation on Wednesday January 12, 2011, 12:34 pm EST

In the news release, Team Challenge Endurance Training Program Generates $8 Million for Crohn’s & Colitis Foundation in 2010, issued 11-Jan-2011 by Crohn’s & Colitis Foundation over PR Newswire, we are advised by the company that the third paragraph, first sentence, should read “…Roberto Martinez from the Bachelorette” rather than “…Fernando Martinez from the Bachelorette” as originally issued inadvertently. the complete, corrected release follows:

Team Challenge Endurance Training Program Generates $8 Million for Crohn’s & Colitis Foundation in 2010

Program offers runners and walkers the ability to make a difference in the lives of digestive disease patients in 2011 through its world-class destination race training

NEW YORK, Jan. 11, 2011 /PRNewswire/ — In 2010, over 2,000 people ran, walked, or cycled with the Crohn’s & Colitis Foundation’s endurance training and fundraising program, Team Challenge. These participants at all fitness levels raised $8 million for research, education, and support services for patients suffering from Crohn’s disease and ulcerative colitis, chronic and often debilitating digestive diseases affecting over 1.4 million Americans.

To view the multimedia assets associated with this release, please click prnewswire.com/news-releases/team-challenge-endurance-training-program-generates-8-million-for-crohns–colitis-foundation-in-2010-113291069.html

“It was amazing to see the number of people running in the race for this cause,” says Mike McCready, lead guitarist for Pearl Jam, who supported and celebrated with participants during race weekend at the Zappos.com Rock ‘n’ Roll Las Vegas Half Marathon, alongside other celebrities including Ali Fedotowsky and fiance Roberto Martinez from the Bachelorette; and meteorologist Bob Van Dillen from HLN’s “Morning Express with Robin Meade.” “As a Crohn’s patient I am grateful that Team Challenge is helping to raise much-needed awareness about this disease and ulcerative colitis. it is so important that people understand what patients go through and that patients understand that they are not alone in their fight.”

In 2010, Team Challenge participants completed the Centurion Cycling’s Blue Mountain race; the 13.1 Boston Marathon; the Napa-to-Sonoma Wine Country Half Marathon; and the Zappos.com Rock ‘n’ Roll Las Vegas Half Marathon.

And this month, the Foundation invites runners and walkers of all levels around the country learn more about how they can challenge themselves, change lives, and help find cures while training for world-class destination races taking place during summer 2011.

Those interested in learning more about training for an upcoming race can attend an information meeting, which are taking place across the country in January, February, and March. Training takes place over 16-weeks in group sessions led by professional coaches while participants raise much-needed awareness of and funds for Crohn’s and colitis research, education, and support initiatives. find a local information meeting at ccteamchallenge.org

Team Challenge participants who sign up will train for either the June 4 Virginia Half Marathon; the June 26 Kona Half Marathon; or the July 17 Napa-to-Sonoma Wine Country Half Marathon. during the Virginia Wine Country Half Marathon, runners and walkers will experience a fast and peaceful course through the winding country roads of Northern Virginia through hillside vineyards, expansive horse farms, and historic estates. the Kona Half Marathon takes place on the beautiful Kona Coast, and offers views of the ocean, mountains, and lava fields of Hawaii. during the Napa-to-Sonoma Wine Country Half Marathon, participants will take in rolling vineyards of the Carneros wine region. for all races, event weekend kicks off with a pasta party and concludes with a finish line bash.

This spring, Team Challenge will launch its Triathlon program that will train participants to swim, bike, and run the TriRock Triathlon Series San Diego race on September 11, 2011.

About Crohn’s Disease & Ulcerative Colitis

Crohn’s disease and ulcerative colitis are painful, medically incurable illnesses that attack the digestive system. Crohn’s disease may attack anywhere from the mouth to the anus, while ulcerative colitis inflames only the large intestine (colon). Symptoms may include abdominal pain, persistent diarrhea, rectal bleeding, fever and weight loss. Many patients require hospitalization and surgery.  These illnesses can cause severe complications, including colon cancer in patients with long-term disease. Some 1.4 million American adults and children suffer from Crohn’s disease or ulcerative colitis, with as many as 150,000 under the age of 18.  Most people develop the diseases between the ages of 15 and 35.

About the Crohn’s & Colitis Foundation

The Crohn’s & Colitis Foundation of America’s mission is to cure Crohn’s disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases. the Foundation ranks third among leading health non-profits in the percentage of expense devoted to research toward a cure, with more than 81 cents of every dollar the Foundation spends goes to mission-critical programs. the Foundation consistently meets the standards of organizations that monitor charities, including the Better Business Bureau’s Wise Giving Alliance (give.org) and the American Institute of Philanthropy (charitywatch.org). for more information, contact the Foundation at 800-932-2423 or visit ccfa.org. Join CCFA on Facebook at apps.facebook.com/supportccfa/and follow CCFA on Twitter at twitter.com/ccfa.  

Related Links

Team Challenge Endurance Training Program

Crohn’s & Colitis Foundation of America